Drug
Parathyroid Hormone clinical trials
Also written rhPTH(1-84), Preotact, NPSP558 and ALX1-11.
- studies test it
- 33
- open now
- 0
- in phase 3
- 16
- first study started
- 1995
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1999 | 2 |
| 2000 | 2 |
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 7
- Phase 3
- 16
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 12
Shire (14) · Nycomed (3) · Takeda (2) · University of Pittsburgh (2) · University of Aarhus (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Columbia University (1) · Zosano Pharma Corporation (1)
Often tested with
Tested in the same studies.
Teriparatide (3) · Risedronic Acid (1) · Ibandronic Acid (1) · Strontium ranelate (1) · Alendronate (1) · Parathyroid hormone-related peptide (1-36) (1)
Studies
Open first, then newest update. How each study uses Parathyroid Hormone is read from its arms, and is right about nine times in ten.
Testing it · 33
- HEXT (Hypo EXTended): Effect of PTH on Skeleton in HypoparathyroidismCompletedPhase 3Columbia UniversityNCT01199614Written as open-label PTH(1-84)
- A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy AdultsCompletedPhase 1TakedaNCT05137730Written as rhPTH(1-84)
- A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)CompletedPhase 4ShireNCT03324880Written as rhPTH (1-84)
- A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic HypoparathyroidismWithdrawnPhase 3ShireNCT03878953Written as rhPTH(1-84)
- Safety and Efficacy Study of rhPTH(1-84) in Subjects With HypoparathyroidismTerminatedPhase 3ShireNCT03364738Written as rhPTH(1-84)
- A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in HypoparathyroidismCompletedPhase 4ShireNCT02910466Written as rhPTH(1-84)
- A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in HungaryCompletedPhase 3ShireNCT01455181Written as NPSP558
- Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)CompletedPhase 3ShireNCT01268098Written as NPSP558
- Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult SubjectsCompletedPhase 1ShireNCT03150108Written as rhPTH(1-84)
- Use of NPSP558 in the Treatment of HypoparathyroidismCompletedPhase 3ShireNCT00732615Written as NPSP558
- Calcium Supplementation in Postmenopausal WomenCompletedPhase 3ShireNCT00172172Written as PTH/Calcium
- A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)CompletedPhase 3ShireNCT01297309Written as NPSP558
- Open Label ExtensionCompletedPhase 3ShireNCT00172120Written as ALX1-11
- A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal OsteoporosisCompletedPhase 2ShireNCT00172107Written as ALX1-11 50 mcg
- Open Label Extension Study of PREOSCompletedPhase 3ShireNCT00172133Written as ALX1-11 (drug)
- TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal OsteoporosisCompletedPhase 3ShireNCT00172081Written as ALX1-11
- ADD-ON Study to Existing Hypoparathyroidism StudiesStatus unknownPhase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00856401Written as PTH1-84 in parent study
- A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo PenCompletedPhase 1Zosano Pharma CorporationNCT02478879Written as ZP-PTH
- 7 Day Continuous Parathyroid Hormone IV InfusionCompletedEarly Phase 1University of PittsburghNCT00377312Written as Parathyroid Hormone (1-34)
- Parathyroid Hormone (PTH) With Alendronate for OsteoporosisCompletedPhase 2Helen Hayes HospitalNCT00005006Written as Parathyroid Hormone
See all 33 studies that test Parathyroid Hormone →
As the comparator · 2 — what is tested is compared with Parathyroid Hormone
Codes
What other systems call Parathyroid Hormone · ClinicalTrials.gg INT007959
- MeSH (NLM) D010281Parathyroid HormoneOne source ClinicalTrials.gov
- UNII (FDA) N19A0T0E5JPARATHYROID HORMONEConfirmed FDA, Wikidata
- RxNorm 1427222One source FDA
- Wikidata Q72499539ParathyroidConfirmed FDA, Wikidata
- NCI Thesaurus C62555Recombinant Parathyroid HormoneOne source FDA
- DrugBank DB05829One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D010281 | Parathyroid Hormone | One source ClinicalTrials.gov |
| UNII (FDA) | N19A0T0E5J | PARATHYROID HORMONE | Confirmed FDA, Wikidata |
| RxNorm | 1427222 | — | One source FDA |
| Wikidata | Q72499539 | Parathyroid | Confirmed FDA, Wikidata |
| NCI Thesaurus | C62555 | Recombinant Parathyroid Hormone | One source FDA |
| DrugBank | DB05829 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.